Educational material about research reagents; not medical advice, sports coaching, or human-use instructions.

The goal phrase "peptides for muscle" is rare as a target query; practical traffic more often arrives via "IGF-1 LR3" and myostatin-pathway molecules (ACE-083, bimagrumab). Both paths are scientifically loose: one topic bucket still mixes IGF signaling, myostatin/activin pathway inhibitors, GH secretagogues, recovery peptides (BPC/TB), and lab RUO vials. Longeva hub does not sell a "mass-gain program" or rank a "best hypertrophy peptide". This page is a shelf map: who owns the muscle-growth commercial aisle, where hub wiki and editorial pillars live, and where the research use only (RUO) boundary sits.

Regena as canonical owner of the muscle aisle

LayerWhereWhat you get
Muscle growth RUO catalogRegena · muscle growthIGF-1 LR3, ACE-083, bimagrumab (BYM338) as research samples + COA
Deep catalog guideRegena · IGF / myostatin shelfMolecule table, LOT/COA, no "best for mass" ranking
IGF-1 LR3 pillar (hub)molecule structure and signalingWhat models measured, not lifestyle promises
Myostatin pathway (hub)ACE-083, bimagrumabFollistatin-Fc / anti-ActRII research context
GLP-1 / weight lossweight-loss shelf, IncretinSemaglutide ≠ IGF-1 LR3; different metabolic axis
Recovery / jointsRegena · BPC/TBConnective tissue repair, not hypertrophy shelf
GH secretagoguesEvity · MK-677, ipamorelin, CJC-1295GH axis; adjacent cluster, does not replace IGF/myostatin shelf

Regena is the canonical owner of muscle-growth / IGF / myostatin SKUs in our network. Hub stays editorial + navigation without a buy CTA on Regena SKUs.

Two biological axes on the muscle growth shelf

The Regena muscle growth aisle groups different mechanisms that casual search often merges into one "anabolic" bucket:

  • IGF pathway. IGF-1 LR3 models signaling through the IGF-1 receptor in cell and animal systems. That is not the same as stimulating pituitary GH secretion (GH secretagogue).
  • Myostatin / activin pathway. ACE-083 (follistatin-Fc) and bimagrumab (BYM338) (anti-ActRII) were studied as inhibitors of TGF-β superfamily signals that limit muscle growth in models. Clinical bimagrumab programs targeted other indications, not "sports mass gain".

IGF-1 LR3 and a myostatin-pathway inhibitor are different molecule classes with different protocol readouts. This map does not answer "which is better for mass".

IGF-1 LR3, ACE-083, bimagrumab: where to read about each

ClusterMoleculeHub wikiHub editorialRUO on Regena
IGF pathwayIGF-1 LR3wikiresearch guidecard
Myostatin / activinACE-083wikifollistatin-Fc reviewcard
Myostatin / activinBimagrumab (BYM338)wikianti-ActRII contextcard

Neutral hub reference: hub PDP IGF-1 LR3 (buy on Regena).

RUO framing

  • A RUO vial carries INN and fill weight; COA describes batch analytics (identity, purity, assay), not sports outcomes.
  • In vitro myotube or in vivo model data describe readouts inside the lab protocol and do not transfer to dosing outside it.
  • Myostatin inhibitors in clinic were studied for other indications; an RUO antibody sample ≠ a finished drug product.
  • "Mass gain" and "hypertrophy" in marketing describe the search topic, not a verified vial effect.

Three adjacent aisles confused with muscle growth

Query / topicActual destinationWhy not muscle shelf
Semaglutide, Mounjaro, weight losshub · weight loss, IncretinGLP-1 / incretin axis, not IGF-1R signaling
BPC-157, TB-500, recoveryRegena · BPC/TBConnective tissue, not IGF/myostatin shelf
MK-677, ipamorelin, CJC-1295Evity · GH axisGH secretagogue cluster, different axis

Brand chooser: buy peptides · pick a brand.

Proteins and antibodies: why purity is the wrong metric here

This is the analytically hardest aisle in the catalog, because what sits on it is not peptides but large proteins and a monoclonal antibody. The line researchers are used to for peptides, "HPLC purity 98%", does not describe what determines whether this material is fit for use.

  • IGF-1 LR3 is a roughly 83-amino-acid protein with disulfide bonds. Its behaviour depends on composition and on correct folding. Mis-paired disulfides give the same mass and a similar purity figure while being a different object. Purity does not report this.
  • Aggregation is a separate question. Proteins form dimers and higher aggregates in solution and after lyophilisation. SEC (size-based separation) detects them; a standard reverse-phase column does not. A report without SEC says nothing about aggregation.
  • Bimagrumab (BYM338) is an antibody, not a peptide. The relevant checks are heavy- and light-chain integrity (SDS-PAGE or CE), an aggregate profile, and where available target-binding confirmation. Asking for "HPLC purity" on a mAb is asking from the wrong method.
  • ACE-083 is an Fc-fusion construct (follistatin-Fc). For fusion proteins the absence of clipped fragments matters additionally, because partial proteolysis leaves material looking "pure" by peak area while being incomplete.
  • Endotoxin and sterility. For research-grade protein material this is standard documentation, and its absence is a quality signal about the supplier in its own right.
  • LOT match against the PDF in the COA archive; verify a lot at /verify/{lot}.

Working rule for this aisle: ask which methods produced the report, not only which number it shows. For an antibody or a fusion protein, "98% by HPLC" is either an incomplete picture or the wrong method entirely.

Three mistakes in mass-gain queries

  1. "Best peptide for mass gain". Hub does not rank. Identify the mechanism first, then open wiki/editorial for that molecule.
  2. Mix muscle shelf with fat loss. Different aisles: GLP-1 on Incretin, IGF/myostatin on Regena.
  3. Read clinical trial percentages as a vial promise. Trial numbers describe the studied drug in a trial protocol, not a Telegram RUO vial.

IGF and myostatin molecule reference

Longeva hub · navigational only · does not replace a lab protocol.